News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cannabis Science Inc. Initiates HIV TAT Anti-Viral Drug Development Program; CS-TATI-1 Lead Hit Discovery Commenced for Pre-Clinical Proof of Concept Development



6/5/2012 11:00:25 AM

COLORADO SPRINGS, Colo.--(BUSINESS WIRE)--Cannabis Science (CBIS.OB) announced today the initiation of a research program to explore the commercial development of Phytocannabinoid-based therapeutics for drug resistant HIV infection. The program will facilitate an antiviral investigation of Phytocannabinoids inhibition of HIV TAT. Cannabis Science is a publicly traded, pioneering U.S. Biotech Company developing pharmaceutical products for global public health challenges.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES